A New Framework for Assessing Digital Health Technologies

By HEOR Staff Writer

October 23, 2023

Digital Health Technologies

The Importance of Developing a Brand-New Structure

The field of digital health technologies (DHTs), which offers novel solutions for the delivery of healthcare, is undergoing rapid development. However, doing an evaluation of their usefulness presents a novel obstacle due to the fact that conventional frameworks for health technology such as pharmaceuticals and medical equipment cannot be directly applied to them. The Peterson Health Technology Institute (PHTI) has established a value assessment framework to guide evaluations of digital health technologies (DHTs), with the goals of creating evidentiary standards for technology developers and assisting organisations in adopting impactful DHTs. This methodology is illustrated below.

The Framework of the Peterson Health Technology Institute

The evaluation of the value of DHTs must pay close attention to the ways in which they affect the economy. DHTs are projected to improve care outcomes while simultaneously reducing overall costs, or give dramatically improved access at significantly cheaper costs than other options. This is in contrast to new medications, which often increase the cost to the health system. Because of the one-of-a-kind characteristics of DHTs, the PHTI paradigm places a greater emphasis on cost-effectiveness analysis over long-term cost-benefit analysis.

The methodology also takes into account the larger economic benefits of DHTs, such as increases in productivity as well as decreases in the amount of time as well as money spent by families and caregivers. However, these advantages will not be considered in the major study of how the budget would be impacted.

Digital Health Technologies

The PHTI’s approach for evaluating DHTs is a significant step towards standardising the evaluation of these technologies and marks an important step in that direction. The framework will guide technology developers in their product development by defining clear and thorough criteria of evidence, and it will assist healthcare organisations in making educated decisions about using DHTs.

The PHTI’s framework will, in the end, contribute to improved health outcomes as well as cost savings in the healthcare sector. This will be accomplished by guaranteeing that only the DHTs that are the most effective and cost-efficient will be adopted.

Reference url

Recent Posts

medtech market access strategy
Prioritizing a Comprehensive Medtech Market Access Strategy Through Stakeholder Engagement

By João L. Carapinha

June 9, 2026

An effective medtech market access strategy must begin at the concept stage by simultaneously addressing patient needs, clinical workflows, regulatory requirements, and payer expectations rather than defaulting to FDA clearance as the sole priority. Startups that ignore this broader view risk bui...
HIV Weekly Treatment Options
Potential for Advancements in HIV Weekly Treatment Options

By João L. Carapinha

June 9, 2026

HIV Weekly Treatment Options took a major step forward as Gilead and Merck reported that their investigational once-weekly combination of islatravir and lenacapavir successfully met the primary endpoint in two Phase 3 trials. The oral regimen maintained viral suppression in adults already control...
Tovorafenib clinical assessment
Tovorafenib Clinical Assessment Outcomes and Methodological Challenges

By João L. Carapinha

June 9, 2026

The Tovorafenib clinical assessment conducted under the EU Joint Clinical Assessment process has exposed critical shortcomings in the evidence base for treating BRAF-altered pediatric low-grade glioma. Despite the therapy’s potential, reviewers concluded that robust comparative data is absent for...